Angiopoietin-1 is essential in mouse vasculature during development and in response to injury

Journal of Clinical Investigation

Volumn 121, Issue 6, 2011, Pages 2278-2289

  Jeansson, Marie ^a   Gawlik, Alexander ^b   Anderson, Gregory ^c   Li, Chengjin ^a   Kerjaschki, Dontscho ^d   Henkelman, Mark ^c   Quaggin, Susan E ^a,e  

^a MOUNT SINAI HOSPITAL   (Canada)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Toronto Centre for Phenogenomics   (Canada)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CRE RECOMBINASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DIABETIC NEPHROPATHY; EMBRYO; FIBROSIS; GENE DELETION; GLOMERULUS BASEMENT MEMBRANE; HEART DEVELOPMENT; MALE; MICROANGIOPATHY; MICROVASCULARIZATION; MOUSE; NONHUMAN; ORGAN INJURY; PERICYTE; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RENAL PROTECTION; UPREGULATION; VASCULARIZATION; WOUND HEALING;

ANGIOPOIETIN-1; ANIMALS; BLOOD VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FETAL HEART; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; KIDNEY GLOMERULUS; LIVER; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PERICYTES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TIE-1; RECOMBINANT FUSION PROTEINS; WOUND HEALING;

EID: 79957880117     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI46322     Document Type: Article

References (42)

1. Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol. 2002;13(2):544-550. (Pubitemid 34106299)
2. Uemura A, et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest. 2002;110(11):1619-1628. (Pubitemid 35424240)
3. Suri C, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171-1180. (Pubitemid 27010101)
4. Partanen J, Dumont DJ. Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development. Curr Top Microbiol Immunol. 1999;237:159-172.
5. Tachibana K, Jones N, Dumont DJ, Puri MC, Bernstein A. Selective role of a distinct tyrosine residue on Tie2 in heart development and early hematopoiesis. Mol Cell Biol. 2005;25(11):4693-4702. (Pubitemid 40705772)
6. Fiedler U, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004;103(11):4150-4156. (Pubitemid 38685356)
7. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006;27(12):552-558. (Pubitemid 44780853)
8. van Meurs M, Kümpers P, Ligtenberg JJ, Meertens JH, Molema G, Zijlstra JG. Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target? Crit Care. 2009;13(2):207.
9. Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care. 2004;27(12):2918-2924. (Pubitemid 39565059)
10. Conroy AL, et al. Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (noncerebral) malaria from uncomplicated malaria. Malar J. 2009;8:295.
11. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis. 2000;26(2):99-109. (Pubitemid 30158089)
12. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A. 2002;99(12):8219-8224. (Pubitemid 34651033)
13. Brown LF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992;176(5):1375-1379.
14. Breyer MD, et al. Mouse Models of Diabetic Nephropathy. J Am Soc Nephrol. 2005;16(1):27-45. (Pubitemid 43073154)
15. Brosius FC III, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009; 20(12):2503-2512.
16. Eremina V, Wong MA, Cui S, Schwartz L, Quaggin SE. Glomerular-specific gene excision in vivo. J Am Soc Nephrol. 2002;13(3):788-793. (Pubitemid 34183947)
17. Foo SS, et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell. 2006;124(1):161-173. (Pubitemid 43069317)
18. Eremina V, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003; 111(5):707-716. (Pubitemid 36278589)
19. Eremina V, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358(11):1129-1136. (Pubitemid 351398487)
20. Satchell SC, Anderson KL, Mathieson PW. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol. 2004;15(3):566-574. (Pubitemid 38294786)
21. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Developmental Cell. 2008;14(1):25-36.
22. Thurston G, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286(5449):2511-2514. (Pubitemid 30026340)
23. Armulik A, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557-561.
24. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451-487. (Pubitemid 351522745)
25. Sison K, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol. 2010;21(10):1691-1701.
26. Staton CA, Valluru M, Hoh L, Reed MW, Brown NJ. Angiopoietin-1, angiopoietin-2 and Tie-2 receptor expression in human dermal wound repair and scarring. Br J Dermatol. 2010;163(5):920-927.
27. Costa RA, Ruiz-de-Souza V, Azevedo Jr GM, Vaz NM, Carvalho CR. Effects of strain and age on ear wound healing and regeneration in mice. Braz J Med Biol Res. 2009;42(12):1143-1149.
28. Roberts AB, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83(12):4167-4171. (Pubitemid 16057012)
29. Cho CH, et al. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. Proc Natl Acad Sci U S A. 2006;103(13):4946-4951.
30. Cho C-H, et al. Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res. 2005;97(1):86-94. (Pubitemid 40982326)
31. Vikkula M, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996;87(7):1181-1190. (Pubitemid 27010102)
32. Takakura N, Kidoya H. Maturation of blood vessels by haematopoietic stem cells and progenitor cells: involvement of apelin/APJ and angiopoietin/ Tie2 interactions in vessel caliber size regulation. Thromb Haemost. 2009;101(6):999-1005.
33. Zhu Y, Lee C, Shen F, Du R, Young WL, Yang GY. Angiopoietin-2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain. Stroke. 2005;36(7):1533-1537. (Pubitemid 40967525)
34. Kim W, et al. COMP-Angiopoietin-1 Ameliorates Renal Fibrosis in a Unilateral Ureteral Obstruction Model. J Am Soc Nephrol. 2006;17(9):2474-2483. (Pubitemid 44300963)
35. Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes. 2009;58(7):1471-1478.
36. Eremina V, et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol. 2006;17(3):724-735.
37. Lee S, et al. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol Dial Transplant. 2007;22(2):396-408. (Pubitemid 46189882)
38. Liu P, Jenkins NA, Copeland NG. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 2003;13(3):476-484. (Pubitemid 36395405)
39. Joyner AL. Gene Targeting A Practical Approach. New York, New York, USA: Oxford University Press; 2000.
40. Dymecki SM. Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice. Proc Natl Acad Sci U S A. 1996;93(12):6191-6196. (Pubitemid 26190826)
41. Walls JR, Coultas L, Rossant J, Henkelman RM. Three-dimensional analysis of vascular development in the mouse embryo. PLoS One. 2008;3(8):e2853.
42. Ema M, Takahashi S, Rossant J. Deletion of the selection cassette, but not cis-acting elements, in targeted Flk1-lacZ allele reveals Flk1 expression in multipotent mesodermal progenitors. Blood. 2006;107(1):111-117. (Pubitemid 43053531)